Accendra Health Details $1.5B Debt Optimization, Reports Q1 Loss Amid Revenue Decline
ACH has more than doubled off its 52-week low of $1.84.
Summary
Accendra Health reported a Q1 loss and declining revenue, but the filing's most critical aspect is the detailed plan for a $1.5 billion debt restructuring, which secures near-term liquidity by extending maturities at higher interest rates.
Key Events · Financing and Capital Events · ACH
-
Balance Sheet Optimization
The company announced commitments to refinance over $1.5 billion in debt, including extending the Term Loan A and Revolving Credit Facility maturities, which were previously classified as current liabilities.
-
New Debt Terms
The restructuring involves exchanging existing notes for new 9.000% senior secured first lien notes due 2032 and 9.750% senior secured second lien notes due 2033.
-
Q1 Financial Performance
Reported a net loss of $6.47 million, an improvement from the prior year's $24.98 million net loss (which included discontinued operations). However, loss from continuing operations worsened to $6.47 million from $3.81 million year-over-year.
-
Revenue Decline
Net revenue decreased by 6.8% to $627.78 million, primarily due to terminated commercial payor contracts.
Analysis · ACH · Trade & Services
Accendra Health's first-quarter report highlights a critical balance sheet optimization transaction, securing commitments to refinance over $1.5 billion in debt. This move addresses significant near-term maturities, including the Term Loan A and Revolving Credit Facility, which were classified as current liabilities. While averting an immediate liquidity crisis, the restructuring involves new senior secured notes with higher interest rates (9.000% and 9.750%). Operationally, the company reported a 6.8% revenue decline and an increased loss from continuing operations, signaling ongoing challenges despite the crucial debt relief.
At the time of this filing, ACH was trading at $3.96 on NYSE in the Trade & Services sector, with a market capitalization of approximately $302.7M. The 52-week trading range was $1.84 to $9.55. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.